<p
>Cambridge, MD, June 15 — FSIF COVID BioScience, a biotechnology company focused on harnessing the power of the human immune system to diagnosis and treat Covid-19, announced today that it just filed a new patent for the Company’s innovative FSIF(FullSpectrumInterferonFingerprint)COVID-19test. While thetechnology behind thisnewly filed patent will serve as an accurate diagnostic for COVID-19, its real value is the ability stratify patients into degrees of disease severity as noted in the grid below:
Due to the complexity of Corona viruses like the one that causes COVID-19, a number of features from this virus block and disrupt our complex but usually very effective immune system. “Our immune biomarker test identifies and quantifies the human immune system’s response to the virus and uses this information to identify those Covid-19 patients who are potentially at risk of developing a more severe case of the virus” Dr. Robert Figliozzi, Chief Science Officer at FSIF Covid Biosciences. Since each patient infected with Covid-19 reacts differently to the virus, the Company is integrating artificial intelligence and machine learning into the technology to utilize the test to help determine the likely course of the disease for each individual patient. In addition, “understanding how an individual patient is likely to respond to the disease will help alleviate many of the burdens that this disease places on our healthcare system and our society as well as allow physicians and other healthcare professionals to allocate limited resources where they are needed most” noted Company CEO David Spiegel.
“The Company is excited to be receiving help and support from some of the nation’s leading research university hospitals and lab groups as it performs the necessary validation trials. COVID-19 is an issue for the entire planet and FSIF COVID BioScience is eager to contribute to the solution from our home on the Eastern Shore of Maryland” said Dr. Figliozzi.
ABOUT FSIF COVID BIOSCIENCE, INC.
FSIF COVID BioScience, Inc. is an innovative, precision diagnostics company dedicated to the discovery of targeted diagnostic tools for COVID-19. The Company’s patent pending technology interrogates the human immune system to improve the diagnosis and treatment of COVID-19. Originally developed in collaboration with FDA scientists to understand and quantify the human immune response to viral infections, FSIF Covid BioScience has deployed the technology to design a test capable of rapidly and accurately detecting the presence of Covid-19.
Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release are forward-looking statements, including statements regarding the Company’s ability to develop, commercialize and achieve market acceptance of its products and services, its research and development efforts, and other matters regarding the business of the Company. In some cases, you can identify forward-looking statements by the words “may,” “will,” “expect,” “plan,” “believe,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. The Company cautions that forward-looking statements are based on a combination of facts and factors currently known and projections of the future, about which the Company cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. The Company undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
FSIF COVID-19 is not an FDA approved test and is not intended to diagnose, treat or cure any disease.
CONTACT INFORMATION:
FSIF COVID BioScience
David Spiegel
(215) 512-8999
This email address is being protected from spambots. You need JavaScript enabled to view it.